Anzeige
Mehr »
Mittwoch, 01.10.2025 - Börsentäglich über 12.000 News
Globaler Gamechanger: CiTech expandiert in Europa - neue Chancen für Investoren!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2ACV2 | ISIN: ES0167733015 | Ticker-Symbol: ORN
Tradegate
01.10.25 | 18:59
3,155 Euro
+5,87 % +0,175
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ORYZON GENOMICS SA Chart 1 Jahr
5-Tage-Chart
ORYZON GENOMICS SA 5-Tage-Chart
RealtimeGeldBriefZeit
3,0903,16520:46
3,0903,16520:16

Aktuelle News zur ORYZON GENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14:06Oryzon Genomics, S.A.: ORYZON Strengthens Patent Portfolio for iadademstat with European Grant Decision Covering Combinations with PD1/PD-L1 Inhibitors28MADRID and CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and European leader in epigenetics,...
► Artikel lesen
16.09.Oryzon Genomics, S.A.: ORYZON Strengthens Patent Portfolio for Iadademstat and Vafidemstat with New Decisions to Grant4
27.08.EMA authorises "Restore", Oryzon Genomics' Phase Ib clinical trial on iadademstat in sickle cell anaemia (SCA)4
26.08.Oryzon Genomics - Foray into sickle cell disease332Oryzon Genomics has announced that the European Medicines Agency (EMA) has provided regulatory clearance for a Phase Ib trial of iadademstat in sickle cell disease. The Phase Ib study (named RESTORE)...
► Artikel lesen
25.08.Oryzon Genomics, S.A.: ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease185First iadademstat clinical trial in non-malignant hematological indications MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker:...
► Artikel lesen
ORYZON GENOMICS Aktie jetzt für 0€ handeln
31.07.Oryzon Genomics - Making headway rolling into H225414Oryzon Genomics has reported its Q225 results, summarising an active period. Its programme focused on vafidemstat in borderline personality disorder (BPD) remains a strategic priority, with the Phase...
► Artikel lesen
14.07.Oryzon Genomics, S.A.: ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat1
11.07.Oryzon Genomics - KOL event highlights vafidemstat potential in BPD366At Oryzon Genomics' key opinion leader (KOL) event, vafidemstat's path through Phase III in borderline personality disorder (BPD) was laid out. The significant unmet need was highlighted, as there are...
► Artikel lesen
27.06.ORYZON GENOMICS, S.A.: ORYZON announces the voting results from its Ordinary General Shareholders' Meeting1
25.06.Oryzon Genomics, S.A.: ORYZON to Host Virtual KOL Event on July 9, 20251
24.06.Oryzon Genomics - A step closer to a new treatment paradigm in BPD375Oryzon Genomics has submitted the Phase III clinical trial protocol to the FDA for its lysine-specific demethylase 1 (LSD1) inhibitor, vafidemstat, in borderline personality disorder (BPD), marking...
► Artikel lesen
23.06.Oryzon Genomics, S.A.: ORYZON Announces Submission of Phase III Protocol to FDA to Initiate PORTICO-2 Trial of Vafidemstat in Borderline Personality Disorder (BPD) Patients164PORTICO-2 designed to validate vafidemstat's efficacy in reducing aggression in BPD patientsPrimary endpoint: STAXI-2 Trait Anger (patient-reported)Key secondary endpoint: Overt Aggression Scale-Modified...
► Artikel lesen
23.06.ORYZON GENOMICS, S.A.: ORYZON announces the submission to the FDA of the clinical trial protocol for its Phase III PORTICO-2 trial of vafidemstat in Borderline Personality Disorder patients1
17.06.Oryzon Genomics, S.A.: ORYZON to Attend the 2025 Phelan-McDermid Syndrome (PMS) Congress in Barcelona on June 26-293
27.05.Oryzon Genomics, S.A.: ORYZON to Provide Corporate Progress Updates at Several Events in May-June1
26.05.ORYZON GENOMICS, S.A.: Call of the Ordinary General Shareholders' Meeting of Oryzon Genomics, S.A.2
19.05.Oryzon Genomics - Preparations in place for an active 2025420Q125 saw Oryzon make significant headway towards Phase III for vafidemstat in BPD and clinical advancement for iadademstat across multiple early-stage studies. Operating performance was unsurprising...
► Artikel lesen
12.05.Oryzon Genomics S.A. GAAP EPS of -$0.032
08.05.Oryzon Genomics - €13.3m grant improves operating headroom359Oryzon Genomics has been awarded a €13.26m (US$15m) non-dilutive grant under the Med4Cure initiative, part of the Important Project of Common European Interest (IPCEI) framework, launched in May 2024....
► Artikel lesen
08.05.Oryzon Genomics, S.A.: ORYZON Awarded €13.26 Million Through the First Important Project of Common European Interest (IPCEI) in the Health Sector (Med4Cure Project)156Approximately 15 million USDOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseasesOryzon will explore Aggression in specific subsets of Autism...
► Artikel lesen
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1